timothy sykes logo

Stock News

Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 7/24/2025, 11:33 am ET 7/24/2025, 11:33 am ET | 5 min 5 min read
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling Thumbnail

Iovance Biotherapeutics Inc. stocks have been trading down by -8.65 percent amid cautious market sentiment over regulatory hurdles.

Candlestick Chart

Live Update At 11:32:52 EST: On Thursday, July 24, 2025 Iovance Biotherapeutics Inc. stock [NASDAQ: IOVA] is trending down by -8.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Iovance Biotherapeutics recently released its earnings report, showing some daunting numbers. Revenue came in at $164M, but profitability is where things took a hit. The company showed a negative operating income of over $121M and a net loss of $116M. These figures tell a story of a company struggling with financial health.

Stock prices have reflected this turmoil, fluctuating widely in the past few days. Just on Jul 24, it swung from a high of 4.04 to a low of 3.55, closing at 3.63. Intraday movements were volatile, painting a picture of a precarious situation for shareholders. The revenue per share is at mere cents, showing the pressure on earnings. Despite the promising concepts, the financial ratios raise red flags: a high price-to-sales ratio but negative profit margins could mean a rough road ahead.

With current ratio at 4.2, they hold a decent buffer of cash, but much of it is spent on operational expenses, which are hardly leading to profitability. Analysts have pointed out concerns and revised price targets sharply downward, echoing Goldman Sachs’ sentiment. Investors now face a decision: hold on through this turbulent storm or cut losses?

Market Reactions and Investor Challenges

The market’s heart skipped a beat with news of the CFO transition to Corleen Roche. Initially seen as a strategic move, it backfired. Market sentiment soured upon hearing about the new financial leadership against the backdrop of ongoing financial challenges. Iovance seems to be caught in a perfect storm, with legal troubles squeezing in.

Goldman Sachs’ downgrade served as the tipping point, with a planned launch for the drug Amtagvi taking longer than expected. Delay in drug development can be fatal for biotech firms, where time is equated with financial health. Shareholders are even more anxious as class action lawsuits pile up, alleging misleading statements from the company’s leadership. These are not mere words; allegations question the operational efficiency and integrity of Iovance.

More Breaking News

Market’s reaction is predictable yet severe, with the stock taking a nosedive. It’s the broader implications that concern everyone – trust in the management is shaking, and that takes time to rebuild. Goldman’s new price target seems to reflect the sentiment that investors need to brace themselves for more stormy weather.

Competitive Pressures and Operational Hurdles

Iovance is feeling competitive heat more than ever. Delays in drug approvals can mean losing market momentum to faster-moving competitors. Additionally, the authorized treatment centers, pivotal in delivering profit, are reportedly underperforming. This inefficiency leads to higher patient drop-offs, translating into missed revenue opportunities.

The murmurs about misleading statements have compounded the problem. Investors want transparency, and while the reports about the centers’ inefficiencies circulate, the accountability lens is focused on Iovance’s leadership. Adaptation seems to be slower than necessary, with new leadership trying to navigate these tumultuous waters.

In an industry where medical advances promise profits, uncertainty is the elephant in the room. How they will change the narrative, instill confidence, both in the market and operational level, remains to be seen. Investors seem to have only one question: Can Iovance weather this period and emerge stronger?

Conclusion

In light of current events, Iovance Biotherapeutics faces a grim landscape. The stock price rollercoaster is a reflection of deeper challenges within the company. Upheavals in management, legal predicaments, and operational hurdles paint a picture of a company at a crossroads. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.” This insight could not be more pertinent as Iovance navigates its current challenges.

While safety buffers in the form of ample cash reserves offer some hope, they are not magic bullets in turning financial misfortunes around. For a company that once held glowing promises of innovation, it’s an uphill journey to regain trader confidence and prove true the worth of its innovations in the market. The coming weeks would be crucial in shaping Iovance’s trajectory, as all eyes remain fixated on how the company manoeuvres out of the current storm.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”